



**HYBRID  
MEETING**



**International Alliance for  
Biological Standardization**

**Rockville, Maryland, U.S.A.**

**September 27 - 28, 2022**

## **3<sup>rd</sup> IABS Conference on Next Generation Sequencing for Adventitious Virus Detection in Biologics for Humans and Animals**

**Co-Chaired by US FDA and EDQM**

This face-to-face meeting will focus on the recent expansion of scientific data and the current applications of next generation sequencing technologies for adventitious virus detection in biological products.

This will include presentations on standardization and validation of the technical and bioinformatics steps involved in the NGS workflow and applications of different NGS strategies for characterization and safety evaluation of biologics, including human and animal vaccines, as well as gene therapy, and therapeutic products. Current regulatory expectations will be discussed.

The meeting will bring together representatives from industry, academia, contract research organizations, and international regulatory bodies for developing a scientific consensus regarding recommendations for using NGS for detection of adventitious viruses.

**Co-Chaired by :**



[Register here](#)



**Venue :**

**University of Maryland**

**Institute for Bioscience and  
Biotechnology Research (IBBR)**

### **Scientific Committee:**

- Arifa S. Khan, **U.S. Food and Drug Administration (FDA) – Co-Chair**
- Laurent Mallet, **EDQM – Co-Chair**
- Pieter Neels, **International Alliance for Biological Standardization (IABS)**
- Johannes Blümel, **Paul-Ehrlich Institut (PEI)**
- Jean-Pol Cassart, **GlaxoSmithKline**
- Mia Jakava-Viljanen, **Finnish Food Authority**
- Ivana Knezevic, **World Health Organization (WHO)**
- Carine Logvinoff, **Sanofi**
- Egbert Mundt, **Boehringer-Ingelheim**
- Siemon Ng, **Notch Therapeutics**
- Michael Wall, **Health Canada**